NASDAQ:RPHM
Delisted

Reneo Pharmaceuticals Stock Signals

etoro logo Buy RPHM
*Your capital is at risk
$1.82
+0 (+0%)
At Close: Jan 03, 2025

Latest Data & Signals Issued

Below are some of the latest signals issued for Reneo Pharmaceuticals, Inc.

General

Signal Type Signal Value Data
Score 0.000 70 days ( -18.95 %
Last Price $1.82 0 %
Performance History
7 Days
$1.82 $1.82
0%
30 Days
$1.82 $1.82
0%
12 Mos
$1.65 $1.82
10.30%

6/18

Active Buy Signals

Specific Signals

Short Term
Net score: 25
Signal Type Signal Value Importance Data
High / Low N/A Very Low $1.82 - $1.82
Trend - 3 mos 0 % High Width: 0.00000000000034 %
Pred. range - 3 mos $1.82 - $1.82 Low 0 % - 0 %
Volume Direction Sell High Volume: 1 · Direction: 0
Pivot Short Buy Very Low Jan 02, 2025 - 2 days
RSI Short Pivot Signal Sell Very Low Oct 14, 2024 - 57 days
Short MA 3 mos Sell Low Nov 30, -0001 - N/A days
Long MA 3 mos Sell Medium Nov 30, -0001 - N/A days
Short/Long MA 3 mos Sell Medium Nov 30, -0001 - N/A days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now
Long Term
Net score: 68.5
Signal Type Signal Value Importance Data
Trend - 12 mos 5.89 % Very High Width: 46.51 %
Pred. range - 12 mos $1.42 - $2.08 High -21.83 % - 14.52 %
Short MA 12 mos Buy Very High Sep 24, 2024 - 71 days
Long MA 12 mos Buy Very High Sep 25, 2024 - 70 days
Short/Long MA 12 mos Buy Very High Oct 08, 2024 - 61 days
Pivot Long Sell Low Jan 02, 2025 - 2 days
RSI Long Pivot Signal Sell Low Oct 23, 2024 - 50 days
Bollinger Sell Medium Nov 30, -0001 - N/A days
MACD Neutral High No Dates Stored For This Signal
Click to get the best stock tips daily for free!
ABOUT RENEO PHARMACEUTICALS, INC.
Reneo Pharmaceuticals
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycog...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
4.43% Jun 01
N
NVRI
$19.53
0.87% May 20
RUN
$12.83
15.51% May 06
GLBE
$31.61
4.05% May 05
SAP
$172.39
8.56% May 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE